Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > BioAlliance Pharma Takes Part in Paris MidCap Event September 17-18

Abstract:
BioAlliance Pharma SA (Euronext Paris - Code Isin: FR0010095596 -BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance, announced today that it will take part in the MidCap Event, a forum dedicated to meetings between institutional investors and listed companies from the Euronext Zone, on September 17-18 in Paris.

BioAlliance Pharma Takes Part in Paris MidCap Event September 17-18

Paris, France | Posted on September 10th, 2007

Dominique Costantini, BioAlliance President and CEO, and Nicolas Fellmann, Chief Financial Officer, will meet institutional investors during one-on-one discussions to explain the company's accelerated growth strategy.

The MidCap Event is a forum dedicated to meetings between institutional investors and listed companies from the Euronext Zone.

####

About BioAlliance Pharma SA
BioAlliance Pharma SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance.

The company is currently conducting 3 phase III clinical trials on innovative products. Two products are based on the Lauriad(R) mucoadhesive technology, which allows an early and prolonged release of therapeutic agents at the site of the disease: one authorized product in France and two clinical international phase III trials ongoing (Loramyc(R) and acyclovir Lauriad(R)). One product is based on the Transdrug(R) nanoparticle technology designed specifically for intracellular targeting: one international phase III trial ongoing on primary liver cancer (doxorubicin Transdrug(R)). The company is also developing a New Entities program focused on new targets in oncology and HIV. The company concluded two strategic partnerships in 2007 to sell its Loramyc(R) product, recently launched on the French market, in Europe and in the US.

Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the reference document approved by the AMF on 6 April 2007 under the number R. 07-031, which is available on the AMF website www.amf-france.org or BioAlliance Pharma S.A.'s website http://www.bioalliancepharma.com

For more information, please click here

Contacts:
Katie Ollerenshaw
ANDREW LLOYD & ASSOCIATES
http://www.ala.com


Brighton Business Centre
95 Ditchling Road Brighton
BN1 4ST ENGLAND
Tel: +44 1273 675100
Fax: +44 1273 675400

55 rue Boissonade
75014 Paris FRANCE
Tel: +33 1 56 54 07 00
Fax: +33 1 56 54 07 01

Copyright © BioAlliance Pharma SA

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Nanometrics to Participate in the Citi 2015 Global Technology Conference August 26th, 2015

Nanostart AG: First-half figures 2015 published and new supervisory board elected : Publication of first-half figures 2015 - Shareholders' meeting elected new supervisory board August 22nd, 2015

Harris & Harris Group Portfolio Company, AgBiome, Secures $34.5 Million Series B Financing Led By Bill and Melinda Gates Foundation August 20th, 2015

Harris & Harris Group Reports Financial Statements as of June 30, 2015, and Announces a Stock Repurchase Program August 10th, 2015

Nanomedicine

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

A new technique to make drugs more soluble August 28th, 2015

These microscopic fish are 3-D-printed to do more than swim: Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities August 26th, 2015

Glitter from silver lights up Alzheimer's dark secrets August 25th, 2015

Announcements

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

A new technique to make drugs more soluble August 28th, 2015

Nanocatalysts improve processes for the petrochemical industry August 28th, 2015

Nanolab Technologies LEAPS Forward with High-Performance Analysis Services to the World: Nanolab Orders Advanced Local Electrode Atom Probe (LEAP®) Microscope from CAMECA Unit of AMETEK Materials Analysis Division August 27th, 2015

Events/Classes

Nanometrics to Participate in the Citi 2015 Global Technology Conference August 26th, 2015

Developing Component Scale Composites Using Nanocarbons August 26th, 2015

Nanotechnology that will impact the Security & Defense sectors to be discussed at NanoSD2015 conference August 25th, 2015

Abstract Submission Deadline for “2nd International Conference on Infectious Diseases & Nanomedicine (December 15-18, 2015, Kathmandu, NEPAL)” has been extended to Sept 15. August 20th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic